XOMA Corporation Company Profile (NASDAQ:XOMA)

About XOMA Corporation (NASDAQ:XOMA)

XOMA Corporation logoXOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:XOMA
  • CUSIP: 98419J10
  • Web: www.xoma.com
  • Market Cap: $167.46 million
  • Outstanding Shares: 7,598,000
Average Prices:
  • 50 Day Moving Avg: $18.52
  • 200 Day Moving Avg: $9.80
  • 52 Week Range: $3.96 - $23.72
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -18.00
  • P/E Growth: -0.420
Sales & Book Value:
  • Annual Revenue: $12.31 million
  • Price / Sales: 14.55
  • Book Value: ($3.83) per share
  • Price / Book: -6.16
  • EBITDA: ($30,550,000.00)
  • Net Margins: -329.42%
  • Return on Assets: -155.46%
  • Debt-to-Equity Ratio: -0.49%
  • Current Ratio: 1.08%
  • Quick Ratio: 1.08%
  • Average Volume: 188,966 shs.
  • Beta: 3.2
  • Short Ratio: 17.29

Frequently Asked Questions for XOMA Corporation (NASDAQ:XOMA)

What is XOMA Corporation's stock symbol?

XOMA Corporation trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA Corporation's earnings last quarter?

XOMA Corporation (NASDAQ:XOMA) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($2.08) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.40) by $0.32. The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $1.29 million. The firm's revenue for the quarter was down 69.1% compared to the same quarter last year. View XOMA Corporation's Earnings History.

When will XOMA Corporation make its next earnings announcement?

XOMA Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for XOMA Corporation.

Where is XOMA Corporation's stock going? Where will XOMA Corporation's stock price be in 2017?

4 brokers have issued 12-month price targets for XOMA Corporation's shares. Their predictions range from $19.00 to $38.00. On average, they expect XOMA Corporation's share price to reach $28.50 in the next year. View Analyst Ratings for XOMA Corporation.

What are analysts saying about XOMA Corporation stock?

Here are some recent quotes from research analysts about XOMA Corporation stock:

  • 1. According to Zacks Investment Research, "XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company's flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. " (10/17/2017)
  • 2. Cowen and Company analysts commented, "XOMA released additional data from its Phase II studies of XOMA 358 in patients." (2/1/2017)

Are investors shorting XOMA Corporation?

XOMA Corporation saw a drop in short interest during the month of September. As of September 29th, there was short interest totalling 325,724 shares, a drop of 37.4% from the September 15th total of 520,208 shares. Based on an average daily volume of 176,496 shares, the days-to-cover ratio is presently 1.8 days. Approximately 4.7% of the shares of the stock are sold short.

Who are some of XOMA Corporation's key competitors?

How do I buy XOMA Corporation stock?

Shares of XOMA Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XOMA Corporation's stock price today?

One share of XOMA Corporation stock can currently be purchased for approximately $23.58.

MarketBeat Community Rating for XOMA Corporation (NASDAQ XOMA)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about XOMA Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for XOMA Corporation (NASDAQ:XOMA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $28.50 (20.87% upside)
Consensus Price Target History for XOMA Corporation (NASDAQ:XOMA)
Price Target History for XOMA Corporation (NASDAQ:XOMA)
Analysts' Ratings History for XOMA Corporation (NASDAQ:XOMA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017HC WainwrightReiterated RatingBuy -> Buy$38.00N/AView Rating Details
9/5/2017WedbushUpgradeNeutral -> Outperform$9.00 -> $19.00HighView Rating Details
2/1/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
11/16/2016Ladenburg Thalmann Financial ServicesReiterated RatingNeutralN/AView Rating Details
8/5/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
3/12/2016Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
3/11/2016Royal Bank Of CanadaReiterated RatingSector Perform$2.00N/AView Rating Details
(Data available from 10/18/2015 forward)


Earnings History for XOMA Corporation (NASDAQ:XOMA)
Earnings by Quarter for XOMA Corporation (NASDAQ:XOMA)
Earnings History by Quarter for XOMA Corporation (NASDAQ XOMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2017Q4 2016($2.32)($2.89)$0.50 million$0.50 millionViewN/AView Earnings Details
11/9/2016Q3($2.40)($2.08)$1.29 million$0.64 millionViewN/AView Earnings Details
8/3/2016($0.12)($0.13)$0.84 million$0.40 millionViewN/AView Earnings Details
5/4/2016($0.12)($0.07)$1.17 million$3.96 millionViewN/AView Earnings Details
3/9/2016Q415($0.15)$0.21$4.01 million$48.18 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.18)$3.55 million$2.10 millionViewListenView Earnings Details
8/6/2015Q215($0.18)($0.20)$4.38 million$2.54 millionViewListenView Earnings Details
5/7/2015Q115($0.16)($0.19)$4.31 million$2.65 millionViewListenView Earnings Details
3/11/2015Q414($0.14)($0.12)$10.70 million$4.30 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)($0.17)$7.00 million$5.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)$5.32 million$5.97 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.23)$7.40 million$3.41 millionViewN/AView Earnings Details
3/4/2014Q413($0.19)($0.55)$7.92 million$8.45 millionViewN/AView Earnings Details
11/7/2013Q313($0.18)($0.21)$7.87 million$6.31 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.21)$9.30 million$7.20 millionViewN/AView Earnings Details
11/7/2012Q312($0.21)($0.39)$11.69 million$7.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for XOMA Corporation (NASDAQ:XOMA)
2017 EPS Consensus Estimate: ($2.50)
2018 EPS Consensus Estimate: ($1.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.65)($1.65)($1.65)
Q2 20171$0.38$0.38$0.38
Q3 20171($0.75)($0.75)($0.75)
Q4 20171($0.48)($0.48)($0.48)
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.51)($0.51)($0.51)
Q3 20181($0.47)($0.47)($0.47)
Q4 20181($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)


Dividend History for XOMA Corporation (NASDAQ:XOMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for XOMA Corporation (NASDAQ:XOMA)
Insider Ownership Percentage: 3.02%
Institutional Ownership Percentage: 32.92%
Insider Trades by Quarter for XOMA Corporation (NASDAQ:XOMA)
Institutional Ownership by Quarter for XOMA Corporation (NASDAQ:XOMA)
Insider Trades by Quarter for XOMA Corporation (NASDAQ:XOMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017John VarianDirectorSell39,540$6.24$246,729.60View SEC Filing  
3/21/2017James R. NealVPSell5,105$5.40$27,567.00View SEC Filing  
2/1/2017James R NealVPSell195$4.52$881.40View SEC Filing  
1/9/2017James R. NealVPSell125$5.15$643.75View SEC Filing  
12/21/2016John VarianDirectorSell13,549$5.75$77,906.75View SEC Filing  
12/21/2016Patrick J Md Phd ScannonVPSell3,230$5.75$18,572.50View SEC Filing  
11/1/2016James R. NealVPSell150$5.25$787.50View SEC Filing  
10/7/2016James R. NealVPSell2,500$0.45$1,125.00View SEC Filing  
3/22/2016John VarianCEOSell81,022$0.78$63,197.16View SEC Filing  
3/22/2016Patrick J Md Phd ScannonVPSell14,785$0.78$11,532.30View SEC Filing  
3/22/2016Paul D RubinCMOSell24,194$0.78$18,871.32View SEC Filing  
2/1/2016Patrick J Md Phd ScannonVPSell8,000$1.01$8,080.00View SEC Filing  
12/28/2015Patrick J Md Phd ScannonVPSell8,000$1.37$10,960.00View SEC Filing  
11/23/2015Patrick J Md Phd ScannonVPSell8,000$1.35$10,800.00View SEC Filing  
10/26/2015Patrick J Md Phd ScannonVPSell8,000$1.04$8,320.00View SEC Filing  
7/22/2015Bros. Advisors Lp BakerInsiderSell11,000,000$1.09$11,990,000.00View SEC Filing  
7/15/2015John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
7/15/2015Paul D RubinCMOSell5,000$4.60$23,000.00View SEC Filing  
7/10/2015Paul D RubinCMOSell33,400$4.55$151,970.00View SEC Filing  
6/15/2015John VarianCEOSell10,000$3.64$36,400.00View SEC Filing  
4/15/2015John VarianCEOSell10,000$3.86$38,600.00View SEC Filing  
3/23/2015Paul D RubinCMOSell32,742$3.94$129,003.48View SEC Filing  
3/16/2015John VarianCEOSell10,000$3.72$37,200.00View SEC Filing  
2/2/2015Patrick J Md Phd ScannonVPSell5,000$3.52$17,600.00View SEC Filing  
1/15/2015John VarianCEOSell10,000$3.46$34,600.00View SEC Filing  
1/6/2015Bros. Advisors Lp BakerDirectorSell2,215,400$3.81$8,440,674.00View SEC Filing  
1/2/2015Patrick J Md Phd ScannonVPSell5,000$3.55$17,750.00View SEC Filing  
12/30/2014Bros. Advisors Lp BakerDirectorSell744,000$3.67$2,730,480.00View SEC Filing  
12/19/2014Bros. Advisors Lp BakerDirectorSell1,605,100$4.26$6,837,726.00View SEC Filing  
12/16/2014Bros. Advisors Lp BakerDirectorSell1,033,800$4.46$4,610,748.00View SEC Filing  
12/15/2014John VarianCEOSell10,000$4.49$44,900.00View SEC Filing  
12/15/2014Paul D RubinCMOSell1,600$4.63$7,408.00View SEC Filing  
12/9/2014Bros. Advisors Lp BakerDirectorSell392,353$4.62$1,812,670.86View SEC Filing  
12/4/2014Bros. Advisors Lp BakerDirectorSell2,372,206$4.79$11,362,866.74View SEC Filing  
12/1/2014Patrick J Md Phd ScannonVPSell5,000$5.51$27,550.00View SEC Filing  
11/26/2014James R NealVPSell1,678$5.67$9,514.26View SEC Filing  
11/24/2014James R NealVPSell1,032$5.03$5,190.96View SEC Filing  
11/20/2014Paul D RubinCMOSell5,000$4.55$22,750.00View SEC Filing  
11/13/2014Fred KurlandCFOSell8,773$3.89$34,126.97View SEC Filing  
11/13/2014James R NealVPSell4,387$3.89$17,065.43View SEC Filing  
11/13/2014John VarianCEOSell58,844$3.89$228,903.16View SEC Filing  
11/3/2014Patrick J Md Phd ScannonVPSell5,000$4.33$21,650.00View SEC Filing  
10/28/2014Paul D RubinCMOSell5,000$4.57$22,850.00View SEC Filing  
10/15/2014John VarianCEOSell10,000$3.87$38,700.00View SEC Filing  
10/1/2014Patrick J Md Phd ScannonVPSell5,000$4.09$20,450.00View SEC Filing  
9/15/2014John VarianCEOSell10,000$4.56$45,600.00View SEC Filing  
9/15/2014Paul D RubinCMOSell5,000$4.59$22,950.00View SEC Filing  
9/4/2014Paul D RubinCMOSell10,000$4.56$45,600.00View SEC Filing  
9/2/2014Patrick J Md Phd ScannonVPSell5,000$4.31$21,550.00View SEC Filing  
8/18/2014Paul D RubinCMOSell26,748$4.34$116,086.32View SEC Filing  
8/15/2014Fred KurlandCFOSell10,401$4.31$44,828.31View SEC Filing  
8/15/2014John VarianCEOSell64,823$4.30$278,738.90View SEC Filing  
8/15/2014Patrick J Md Phd ScannonVPSell5,871$4.31$25,304.01View SEC Filing  
8/1/2014Patrick J Md Phd ScannonVPSell5,000$3.83$19,150.00View SEC Filing  
7/15/2014John VarianCEOSell10,000$4.03$40,300.00View SEC Filing  
7/1/2014Patrick J Md Phd ScannonVPSell5,000$4.68$23,400.00View SEC Filing  
6/16/2014John VarianCEOSell10,000$4.54$45,400.00View SEC Filing  
6/16/2014Paul D RubinCMOSell11,580$4.54$52,573.20View SEC Filing  
5/28/2014Paul D RubinCMOSell1,785$4.22$7,532.70View SEC Filing  
5/15/2014John VarianCEOSell10,000$3.55$35,500.00View SEC Filing  
4/15/2014John VarianCEOSell10,000$4.06$40,600.00View SEC Filing  
3/18/2014Fred KurlandCFOSell5,915$6.32$37,382.80View SEC Filing  
3/18/2014John VarianCEOSell21,329$6.32$134,799.28View SEC Filing  
3/18/2014Patrick Md Phd ScannonVPSell3,419$6.32$21,608.08View SEC Filing  
3/18/2014Paul RubinCMOSell17,649$6.31$111,365.19View SEC Filing  
3/18/2014Thomas KleinInsiderSell30,965$6.32$195,698.80View SEC Filing  
3/17/2014John VarianCEOSell10,000$6.03$60,300.00View SEC Filing  
2/18/2014John VarianCEOSell10,000$7.55$75,500.00View SEC Filing  
2/18/2014Paul RubinCMOSell6,000$7.55$45,300.00View SEC Filing  
1/21/2014Paul RubinCMOSell6,000$8.27$49,620.00View SEC Filing  
1/15/2014John VarianCEOSell10,000$8.28$82,800.00View SEC Filing  
1/9/2014Patrick Md Phd ScannonVPSell20,000$8.00$160,000.00View SEC Filing  
12/18/2013Paul RubinCMOSell6,000$5.67$34,020.00View SEC Filing  
12/16/2013John VarianCEOSell10,000$5.44$54,400.00View SEC Filing  
12/2/2013Patrick Md Phd ScannonVPSell20,000$6.00$120,000.00View SEC Filing  
11/27/2013Paul RubinCMOSell4,696$4.54$21,319.84View SEC Filing  
11/18/2013Paul RubinCMOSell1,304$4.08$5,320.32View SEC Filing  
11/15/2013John VarianCEOSell64,932$3.95$256,481.40View SEC Filing  
10/15/2013John VarianCEOSell10,000$4.60$46,000.00View SEC Filing  
9/18/2013Paul RubinCMOSell6,000$4.53$27,180.00View SEC Filing  
9/16/2013John VarianCEOSell10,000$4.59$45,900.00View SEC Filing  
8/19/2013Bros. Advisors Lp BakerDirectorBuy2,757,791$3.62$9,983,203.42View SEC Filing  
8/19/2013Paul RubinCMOSell6,000$3.74$22,440.00View SEC Filing  
8/15/2013John VarianCEOSell61,647$3.87$238,573.89View SEC Filing  
8/14/2013Fred KurlandCFOSell7,498$3.86$28,942.28View SEC Filing  
8/14/2013Patrick Md Phd ScannonVPSell6,002$3.86$23,167.72View SEC Filing  
8/14/2013Paul RubinCMOSell10,520$3.86$40,607.20View SEC Filing  
7/18/2013Paul D RubinCMOSell6,000$4.71$28,260.00View SEC Filing  
7/15/2013John VarianCEOSell10,000$4.81$48,100.00View SEC Filing  
5/29/2013Paul D RubinCMOSell1,797$4.16$7,475.52View SEC Filing  
5/20/2013Paul D RubinCMOSell6,000$0.54$3,240.00View SEC Filing  
11/14/2012Fred KurlandCFOSell9,111$2.56$23,324.16View SEC Filing  
11/14/2012John VarianCEOSell40,587$2.56$103,902.72View SEC Filing  
11/14/2012Patrick J Md Phd ScannonEVPSell8,773$2.56$22,458.88View SEC Filing  
10/29/2012Julian BakerDirectorBuy4,722,666$3.00$14,167,998.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for XOMA Corporation (NASDAQ:XOMA)
Latest Headlines for XOMA Corporation (NASDAQ:XOMA)
americanbankingnews.com logoXOMA Corporation (XOMA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 17 at 11:36 AM
americanbankingnews.com logoHC Wainwright Initiates Coverage on XOMA Corporation (XOMA)
www.americanbankingnews.com - October 17 at 8:30 AM
americanbankingnews.com logoXOMA Corporation (XOMA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 15 at 6:46 AM
americanbankingnews.com logoXOMA Corporation (XOMA) Short Interest Update
www.americanbankingnews.com - October 14 at 1:40 AM
americanbankingnews.com logoMateon Therapeutics (MATN) and XOMA Corporation (XOMA) Financial Contrast
www.americanbankingnews.com - October 13 at 10:28 PM
americanbankingnews.com logo Brokerages Anticipate XOMA Corporation (XOMA) Will Announce Quarterly Sales of $770,000.00
www.americanbankingnews.com - October 11 at 1:52 PM
americanbankingnews.com logoCritical Contrast: XOMA Corporation (XOMA) & Its Rivals
www.americanbankingnews.com - October 6 at 4:28 AM
americanbankingnews.com logoFinancial Comparison: XOMA Corporation (XOMA) and Its Peers
www.americanbankingnews.com - October 5 at 8:26 PM
globenewswire.com logoXOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries - GlobeNewswire (press release)
globenewswire.com - October 5 at 1:40 PM
finance.yahoo.com logoXOMA Announces Multiple New License Agreements for Proprietary Phage Display Libraries
finance.yahoo.com - October 4 at 2:17 PM
americanbankingnews.com logoContrasting XOMA Corporation (XOMA) and DNIB Unwind (BIND)
www.americanbankingnews.com - September 27 at 2:06 AM
americanbankingnews.com logoXOMA Corporation (XOMA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 20 at 6:34 AM
finance.yahoo.com logoXOMA Corporation (XOMA)
finance.yahoo.com - September 19 at 9:51 AM
feeds.benzinga.com logoXOMA to Present at the Cantor Fitzgerald Global Healthcare Conference
feeds.benzinga.com - September 19 at 7:43 AM
seekingalpha.com logoXOMA Out-License Model Catching Waves - Seeking Alpha
seekingalpha.com - September 13 at 9:30 PM
seekingalpha.com logoXOMA (XOMA) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 4:29 PM
globenewswire.com logoXOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics - GlobeNewswire (press release)
globenewswire.com - September 11 at 8:51 AM
finance.yahoo.com logoXOMA Earns $3 Million Milestone Payment from its License Agreement with Nanotherapeutics
finance.yahoo.com - September 11 at 8:51 AM
americanbankingnews.com logoXOMA Corporation (XOMA) versus its Rivals Critical Contrast
www.americanbankingnews.com - September 11 at 4:22 AM
americanbankingnews.com logoFinancial Survey: XOMA Corporation (XOMA) vs. Soligenix (SNGX)
www.americanbankingnews.com - September 9 at 11:06 AM
finance.yahoo.com logoETFs with exposure to XOMA Corp. : September 7, 2017
finance.yahoo.com - September 8 at 10:48 AM
finance.yahoo.com logoXOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 7 at 11:40 AM
finance.yahoo.com logoXOMA to Present at the Rodman and Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 7 at 11:40 AM
americanbankingnews.com logoXOMA Corporation Expected to Post Q3 2017 Earnings of ($0.75) Per Share (XOMA)
www.americanbankingnews.com - September 7 at 6:57 AM
reuters.com logoSwiss stocks - Factors to watch on Sept 6
www.reuters.com - September 6 at 1:37 AM
rttnews.com logoINSM Breathes Easy, XOMA Rises On Analyst Upgrade, CLLS Down On Clinical Hold
www.rttnews.com - September 6 at 1:36 AM
benzinga.com logoMid-Afternoon Market Update: Dow Drops Over 200 Points; Insmed Shares Jump After Positive Results From Lung ... - Benzinga
www.benzinga.com - September 5 at 3:28 PM
seekingalpha.com logoXoma Just Saved Itself Again - Seeking Alpha
seekingalpha.com - August 29 at 9:57 AM
americanbankingnews.com logoComparing Affymax (AFFY) & XOMA Corporation (XOMA)
www.americanbankingnews.com - August 28 at 4:20 PM
americanbankingnews.com logoHead-To-Head Analysis: XOMA Corporation (XOMA) & Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - August 26 at 4:28 PM
americanbankingnews.com logoXOMA Corporation (XOMA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - August 26 at 6:46 AM
finance.yahoo.com logoETFs with exposure to XOMA Corp. : August 25, 2017
finance.yahoo.com - August 25 at 9:14 PM
streetinsider.com logoXOMA (XOMA) Reports Transformational License Pacts for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio
www.streetinsider.com - August 25 at 3:58 PM
nasdaq.com logoMid-Day Market Update: Adamas Pharma Climbs Following FDA Approval of GOCOVRI; Aceto Shares Plummet
www.nasdaq.com - August 25 at 3:58 PM
nasdaq.com logoMid-Afternoon Market Update: GameStop Drops After Mixed Q2 Report; Pure Storage Shares Surge
www.nasdaq.com - August 25 at 3:58 PM
reuters.com logoBRIEF-Xoma announces transformational license agreements for gevokizumab and its IL-1 beta intellectual property portfolio
www.reuters.com - August 25 at 12:53 PM
streetinsider.com logoPre-Open Stock Movers 08/25: (ADMS) (XOMA) (KMDA) Higher; (GME) (ULTA) (VEEV) Lower (more...)
www.streetinsider.com - August 25 at 12:53 PM
finance.yahoo.com logoXOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio
finance.yahoo.com - August 25 at 12:53 PM
finance.yahoo.com logoXOMA Corp. :XOMA-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
finance.yahoo.com - August 17 at 9:30 AM
americanbankingnews.com logoXOMA Corporation to Post Q3 2017 Earnings of ($0.80) Per Share, Wedbush Forecasts (XOMA)
www.americanbankingnews.com - August 16 at 6:26 AM
americanbankingnews.com logoWedbush Reaffirms Hold Rating for XOMA Corporation (XOMA)
www.americanbankingnews.com - August 14 at 5:30 PM
americanbankingnews.com logoXOMA Corporation's (NASDAQ:XOMA) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - August 10 at 3:03 PM
feeds.benzinga.com logoXOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference
feeds.benzinga.com - August 9 at 5:46 PM
globenewswire.com logoXOMA Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 3:22 PM
finance.yahoo.com logoXOMA Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 9:22 AM
americanbankingnews.com logoXOMA Corporation (NASDAQ:XOMA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 1 at 9:23 AM
seekingalpha.com logoXOMA: Another Ligand In The Making?
seekingalpha.com - July 29 at 8:54 AM
seekingalpha.com logoXOMA: Another Ligand In The Making?
seekingalpha.com - July 29 at 8:54 AM
americanbankingnews.com logo$10.56 Million in Sales Expected for XOMA Corporation (XOMA) This Quarter
www.americanbankingnews.com - July 29 at 7:48 AM
americanbankingnews.com logo Analysts Expect XOMA Corporation (NASDAQ:XOMA) Will Post Earnings of $0.34 Per Share
www.americanbankingnews.com - July 27 at 10:35 AM



XOMA Corporation (XOMA) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.